New Risk • May 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Ankündigung • Mar 13
Kumho HT, Inc., Annual General Meeting, Mar 26, 2026 Kumho HT, Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 27, nonggongdanji-gil, jangseong-gun, jeollanam-do, South Korea Reported Earnings • Nov 19
Third quarter 2025 earnings released: ₩12.00 loss per share (vs ₩26.00 profit in 3Q 2024) Third quarter 2025 results: ₩12.00 loss per share (down from ₩26.00 profit in 3Q 2024). Revenue: ₩90.3b (down 21% from 3Q 2024). Net loss: ₩2.38b (down 146% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Ankündigung • Jul 03
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330). SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion.
For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion.
The expected completion of the transaction is July 1, 2025.
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) on July 1, 2025. Kumho HT, Inc. has received the balance of payment for the shares. Ankündigung • Jul 02
Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) acquired an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) from Eco Volt Co.,Ltd. (KOSDAQ:A097780) and Kumho HT, Inc. (KOSE:A214330). Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) entered into agreement to acquire an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) from Eco Volt Co.,Ltd. (KOSDAQ:A097780) and Kumho HT, Inc. (KOSE:A214330) for KRW 26.5 billion on June 11, 2025. A cash consideration of KRW 26.49 billion valued at KRW 1800 per share will be paid by Osung Advanced Materials Co., Ltd. As part of consideration, KRW 26.49 billion is paid towards common equity of Hwail Pharmaceutical Co.,Ltd. Upon completion, Osung Advanced Materials Co., Ltd. will own 23.63% stake in Hwail Pharmaceutical Co.,Ltd. whereas Kumho HT, Inc. will hold 11.10% and Eco Volt Co.,Ltd. will cease to be shareholder of Hwail Pharmaceutical Co.,Ltd. The expected completion of the transaction is July 1, 2025.
Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) completed the acquisition of an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) from Eco Volt Co.,Ltd. (KOSDAQ:A097780) and Kumho HT, Inc. (KOSE:A214330) on July 01, 2025. Ankündigung • Jun 18
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion. SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion.
The expected completion of the transaction is July 1, 2025. Ankündigung • Jun 12
Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) entered into agreement to acquire an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) from Eco Volt Co.,Ltd. (KOSDAQ:A097780) and Kumho HT, Inc. (KOSE:A214330) for KRW 26.5 billion. Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) entered into agreement to acquire an additional 17.75% stake in Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) from Eco Volt Co.,Ltd. (KOSDAQ:A097780) and Kumho HT, Inc. (KOSE:A214330) for KRW 26.5 billion on June 11, 2025. A cash consideration of KRW 26.49 billion valued at KRW 1800 per share will be paid by Osung Advanced Materials Co., Ltd. As part of consideration, KRW 26.49 billion is paid towards common equity of Hwail Pharmaceutical Co.,Ltd. Upon completion, Osung Advanced Materials Co., Ltd. will own 23.63% stake in Hwail Pharmaceutical Co.,Ltd. whereas Kumho HT, Inc. will hold 11.10% and Eco Volt Co.,Ltd. will cease to be shareholder of Hwail Pharmaceutical Co.,Ltd. The expected completion of the transaction is July 1, 2025. Ankündigung • Apr 07
Kumho HT, Inc. (KOSE:A214330) announces an Equity Buyback for KRW 5,000 million worth of its shares. Kumho HT, Inc (KOSE:A214330) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with Hana Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on October 10, 2025. As of April 6, 2025, the company had 1,260,000 shares in treasury within scope available for dividend and had 8,906,848 shares in treasury through other repurchase. Reported Earnings • Mar 21
Full year 2024 earnings released: ₩74.00 loss per share (vs ₩109 loss in FY 2023) Full year 2024 results: ₩74.00 loss per share (improved from ₩109 loss in FY 2023). Revenue: ₩444.9b (up 22% from FY 2023). Net loss: ₩14.9b (loss narrowed 26% from FY 2023). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Ankündigung • Mar 12
Kumho HT, Inc., Annual General Meeting, Mar 25, 2025 Kumho HT, Inc., Annual General Meeting, Mar 25, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 27, nonggongdanji-gil, jangseong-gun, jeollanam-do, South Korea New Risk • Mar 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (₩128.5b market cap, or US$95.5m). Reported Earnings • Mar 15
Full year 2023 earnings released: ₩109 loss per share (vs ₩121 loss in FY 2022) Full year 2023 results: ₩109 loss per share (improved from ₩121 loss in FY 2022). Revenue: ₩364.3b (up 31% from FY 2022). Net loss: ₩20.3b (loss narrowed 11% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. New Risk • Feb 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 59% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding). Ankündigung • Jan 23
Kumho HT, Inc announced that it has received KRW 4.99999955 billion in funding from Eco Volt Co.,Ltd. On January 22, 2024, Kumho HT, Inc closed the transaction. New Risk • Oct 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩132.4b market cap, or US$98.4m). Reported Earnings • May 14
First quarter 2023 earnings released: EPS: ₩10.00 (vs ₩2.00 in 1Q 2022) First quarter 2023 results: EPS: ₩10.00 (up from ₩2.00 in 1Q 2022). Revenue: ₩76.9b (up 19% from 1Q 2022). Net income: ₩1.93b (up 334% from 1Q 2022). Profit margin: 2.5% (up from 0.7% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 18
Full year 2022 earnings released: ₩121 loss per share (vs ₩130 loss in FY 2021) Full year 2022 results: ₩121 loss per share. Revenue: ₩277.8b (up 19% from FY 2021). Net loss: ₩22.6b (loss widened 28% from FY 2021). Reported Earnings • Nov 16
Third quarter 2022 earnings released: ₩1.00 loss per share (vs ₩6.00 profit in 3Q 2021) Third quarter 2022 results: ₩1.00 loss per share (down from ₩6.00 profit in 3Q 2021). Revenue: ₩71.1b (up 33% from 3Q 2021). Net loss: ₩226.9m (down 130% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 13
Third quarter 2022 earnings released: ₩1.00 loss per share (vs ₩6.00 profit in 3Q 2021) Third quarter 2022 results: ₩1.00 loss per share (down from ₩6.00 profit in 3Q 2021). Revenue: ₩71.1b (up 33% from 3Q 2021). Net loss: ₩226.9m (down 130% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Ankündigung • Nov 10
Kumho HT, Inc announced that it has received KRW 8.7 billion in funding from BH Co., Ltd. On November 3, 2022, Kumho HT, Inc amended the terms of the transaction. The company announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for the gross proceeds of KRW 8,700,000,000 on November 3, 2022. The transaction will include participation from BH Co., Ltd. The bonds carry 2% maturity rate, 2% coupon rate and will mature on November 9, 2025. The bonds are 100% convertible into 8,546,168 shares at an conversion price of KRW 1,018. The bonds are convertible from November 9, 2023 and ends on October 9, 2025. The transaction was approved by the board of directors of the company. The transaction is expected to close on November 9, 2022. Ankündigung • Oct 27
Kumho HT, Inc announced that it expects to receive KRW 10 billion in funding from BH Co., Ltd. Kumho HT, Inc announced a private placement series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on October 25, 2022. The transaction will include participation from BH Co., Ltd. The bonds carry 2% maturity rate, 2% coupon rate and will mature on November 9, 2025. The bonds are 100% convertible into 9,578,544 shares at an conversion price of KRW 1,044. The bonds are convertible from November 9, 2023 and ends on October 9, 2025. The transaction was approved by the board of directors of the company. The transaction is expected to close on November 9, 2022. Ankündigung • Sep 28
Kumho HT, Inc (KOSE:A214330) announces an Equity Buyback for KRW 7,000 million worth of its shares. Kumho HT, Inc (KOSE:A214330) announces a share repurchase program. Under the program, the company will repurchase up to KRW 7,000 million worth of its shares pursuant to a contract with Hana Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of September 27, 2022, the company had 0 shares in treasury within scope available for dividend and had 8,906,948 shares in treasury through other repurchase. Reported Earnings • May 18
First quarter 2022 earnings released: EPS: ₩2.00 (vs ₩20.00 in 1Q 2021) First quarter 2022 results: EPS: ₩2.00 (down from ₩20.00 in 1Q 2021). Revenue: ₩64.4b (up 5.9% from 1Q 2021). Net income: ₩444.9m (down 82% from 1Q 2021). Profit margin: 0.7% (down from 4.0% in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS ₩6.00 (vs ₩18.00 loss in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩53.5b (down 12% from 3Q 2020). Net income: ₩759.9m (up ₩2.49b from 3Q 2020). Profit margin: 1.4% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 15
Second quarter 2021 earnings released: ₩8.00 loss per share (vs ₩28.00 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: ₩60.6b (up 47% from 2Q 2020). Net loss: ₩1.02b (loss narrowed 54% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance. Reported Earnings • May 19
First quarter 2021 earnings released: EPS ₩20.00 (vs ₩46.00 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩60.9b (up 12% from 1Q 2020). Net income: ₩2.41b (up ₩5.71b from 1Q 2020). Profit margin: 4.0% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 125 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 21
Full year 2020 earnings released: ₩105 loss per share (vs ₩1.00 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩219.6b (down 13% from FY 2019). Net loss: ₩9.55b (loss widened ₩9.47b from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 27
Kumho HT, Inc, Annual General Meeting, Mar 25, 2021 Kumho HT, Inc, Annual General Meeting, Mar 25, 2021, at 09:01 Korea Standard Time. Is New 90 Day High Low • Feb 24
New 90-day low: ₩2,250 The company is down 21% from its price of ₩2,865 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Auto Components industry, which is up 29% over the same period. Is New 90 Day High Low • Jan 27
New 90-day high: ₩3,315 The company is up 25% from its price of ₩2,655 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Auto Components industry, which is up 41% over the same period. Is New 90 Day High Low • Jan 12
New 90-day low: ₩2,355 The company is down 41% from its price of ₩4,015 on 14 October 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Auto Components industry, which is up 39% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: ₩2,375 The company is down 36% from its price of ₩3,695 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Auto Components industry, which is up 13% over the same period. Ankündigung • Aug 28
Kumho HT, Inc. (KOSE:A214330) agreed to acquire remaining 81% stake in DiNonA Inc. (XKON:A086080). Kumho HT, Inc. (KOSE:A214330) agreed to acquire remaining 81% stake in DiNonA Inc. (XKON:A086080) on August 27, 2020. Ankündigung • Jun 16
S-MAC CO., Ltd. (KOSDAQ:A097780) completed the acquisition of additional 8.22% stake in Kumho HT, Inc. (KOSE:A214330) from Lumimicro Co., Ltd (KOSDAQ:A082800). S-MAC CO., Ltd. (KOSDAQ:A097780) entered into a contract to acquire additional 8.22% stake in Kumho HT, Inc. (KOSE:A214330) from Lumimicro Co., Ltd (KOSDAQ:A082800) for KRW 9.9 billion on January 13, 2020. As part of this transaction, Lumimicro Co., Ltd will sell 2.1 million shares of Kumho for the unit price of KRW 4,700. As part of consideration, down payment of KRW 987 million was paid on January 13, 2020 and the balance of KRW 8.9 billion will be paid on closing on April 30, 2020. As of April 29, 2020, the balance payment of KRW 8.9 billion will be paid on June 30, 2020. This transaction is expected to close on April 30, 2020. As of April 29, 2020, the stock transfer date is June 30, 2020.
S-MAC CO., Ltd. (KOSDAQ:A097780) completed the acquisition of additional 8.22% stake in Kumho HT, Inc. (KOSE:A214330) from Lumimicro Co., Ltd (KOSDAQ:A082800) on June 12, 2020. The transaction is funded through reserved funds 
